FibroGen, Inc.

Equities

FGEN

US31572Q8087

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.35 USD -8.91% Intraday chart for FibroGen, Inc. -3.29% +165.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
FibroGen Shares Jump After CEO Stock Purchase MT
FibroGen Names Deyaa Adib Chief Medical Officer MT
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer CI
Transcript : FibroGen, Inc., Q4 2023 Earnings Call, Feb 26, 2024
FibroGen regains rights to anemia drug from AstraZeneca RE
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (FGEN) FIBROGEN Reports Q4 Revenue $27.1M, vs. Street Est of $38.8M MT
FibroGen, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
FibroGen, Inc. Regains All Rights to Roxadustat from Astrazeneca in the United States and Other Astrazeneca Territories, Except China and South Korea CI
Transcript : FibroGen, Inc. - Special Call
FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network?s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from NASDAQ Biotechnology Index CI
Transcript : FibroGen, Inc., Q3 2023 Earnings Call, Nov 06, 2023
FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (FGEN) FIBROGEN Reports Q3 Revenue $40.1M, vs. Street Est of $36.8M MT
FibroGen Names Interim Chief Executive Thane Wettig as CEO MT
FibroGen, Inc. Appoints Thane Wettig as a Member of the Board CI
FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from S&P Biotechnology Select Industry Index CI
Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023 CI
Analyst recommendations: Hewlett Packard, Apple, Tesla, Mosaic, Rite Aid... Our Logo
Investors cheer on bad data Our Logo
Sector Update: Health Care Stocks Mixed Premarket Wednesday MT
Chart FibroGen, Inc.
More charts
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
3
Last Close Price
2.35 USD
Average target price
1.25 USD
Spread / Average Target
-46.81%
Consensus